Proton Pump Inhibitors and Clopidogrel
Copyright policy )Proton Pump Inhibitors and Clopidogrel
Proton pump inhibitors are often prescribed for patients on clopidogrel to prevent gastrointestinal bleeding complications. Recent data suggest higher rates of adverse cardiovascular events in patients on proton pump inhibitors and clopidogrel, in comparison to patients on clopidogrel only. Both drugs are metabolized by similar pathways of the cytochrome P450 system, so proton pump inhibitors may inhibit the metabolism of clopidogrel to its active metabolite. This article reviews the pharmacodynamic and clinical evidence for this phenomenon.
- MedStar Washington Hospital Center United States
Evidence-Based Medicine, Ticlopidine, Platelet Aggregation, Proton Pump Inhibitors, Risk Assessment, Clopidogrel, Cytochrome P-450 CYP2C19, Humans, Drug Interactions, Aryl Hydrocarbon Hydroxylases, Gastrointestinal Hemorrhage, Biotransformation, Platelet Aggregation Inhibitors
Evidence-Based Medicine, Ticlopidine, Platelet Aggregation, Proton Pump Inhibitors, Risk Assessment, Clopidogrel, Cytochrome P-450 CYP2C19, Humans, Drug Interactions, Aryl Hydrocarbon Hydroxylases, Gastrointestinal Hemorrhage, Biotransformation, Platelet Aggregation Inhibitors
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).2 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!